Danielle Antalffy
Stock Analyst at UBS
(3.67)
# 760
Out of 4,876 analysts
166
Total ratings
50%
Success rate
6.6%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMCI Treace Medical Concepts | Maintains: Neutral | $10 → $8.6 | $5.64 | +52.48% | 6 | May 9, 2025 | |
| ATRC AtriCure | Maintains: Buy | $60 → $58 | $32.37 | +79.18% | 13 | Apr 30, 2025 | |
| INMD InMode | Maintains: Neutral | $19 → $16 | $14.27 | +13.88% | 4 | Apr 29, 2025 | |
| RXST RxSight | Downgrades: Neutral | $45 → $16 | $13.07 | +22.42% | 3 | Apr 9, 2025 | |
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $85.95 | +10.53% | 10 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $106.35 | +22.24% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $4.23 | +18.20% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $134.61 | +9.95% | 12 | Jan 23, 2025 | |
| GKOS Glaukos | Initiates: Buy | $182 | $102.16 | +78.15% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $393.08 | -5.87% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $77.28 | -2.95% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $112 → $107 | $91.12 | +17.43% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $86.40 | +9.95% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $31.98 | +134.52% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $152.51 | +18.03% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $129.44 | +148.76% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $1.98 | +13.92% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $30.41 | +41.40% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $538.89 | -48.41% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $19.12 | +135.36% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $311.75 | -10.18% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $19.02 | +4,237.54% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $10.27 | +36.32% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $80.41 | +24.36% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $10.92 | +9.94% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $57.85 | -48.14% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $41.15 | +9.35% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $171.40 | +60.44% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.57 | +460.22% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $7.22 | +481.72% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.49 | +508.40% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.14 | +1,215.67% | 1 | Sep 1, 2020 |
Treace Medical Concepts
May 9, 2025
Maintains: Neutral
Price Target: $10 → $8.6
Current: $5.64
Upside: +52.48%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $32.37
Upside: +79.18%
InMode
Apr 29, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $14.27
Upside: +13.88%
RxSight
Apr 9, 2025
Downgrades: Neutral
Price Target: $45 → $16
Current: $13.07
Upside: +22.42%
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $85.95
Upside: +10.53%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $106.35
Upside: +22.24%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $4.23
Upside: +18.20%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $134.61
Upside: +9.95%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $102.16
Upside: +78.15%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $393.08
Upside: -5.87%
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $77.28
Upside: -2.95%
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $91.12
Upside: +17.43%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $86.40
Upside: +9.95%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $31.98
Upside: +134.52%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $152.51
Upside: +18.03%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $129.44
Upside: +148.76%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $1.98
Upside: +13.92%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $30.41
Upside: +41.40%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $538.89
Upside: -48.41%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $19.12
Upside: +135.36%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $311.75
Upside: -10.18%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $19.02
Upside: +4,237.54%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $10.27
Upside: +36.32%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $80.41
Upside: +24.36%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $10.92
Upside: +9.94%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $57.85
Upside: -48.14%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $41.15
Upside: +9.35%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $171.40
Upside: +60.44%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.57
Upside: +460.22%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $7.22
Upside: +481.72%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.49
Upside: +508.40%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.14
Upside: +1,215.67%